cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Akebia Therapeutics Inc
47 own
58 watching
Current Price
$1.13
$0.06
(5.61%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
207.87M
52-Week High
52-Week High
2.93
52-Week Low
52-Week Low
0.241
Average Volume
Average Volume
2.99M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization207.87M
icon52-Week High2.93
icon52-Week Low0.241
iconAverage Volume2.99M
iconDividend Yield--
iconP/E Ratio--
What does the Akebia Therapeutics Inc do?
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, as well as with Mitsubishi Tanabe Pharma Corporation for the development and commercialization to vadadustat in Japan and other Asian countries. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Akebia Therapeutics Inc make?
News & Events about Akebia Therapeutics Inc.
PR Newswire
1month ago
Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA PR Newswire...
Zolmax
2 months ago
Akebia Therapeutics (NASDAQ:AKBA Get Rating) and Generation Bio (NASDAQ:GBIO Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, ...
PR Newswire
3 months ago
Akebia Therapeutics Announces Poster Presentation at ASN Kidney Week 2022 Akebia Therapeutics Announces Poster Presentation at ASN Kidney Week 2022 PR Newswire CAMBRIDGE, Mass., Oct. 21, 2022 CAMBRIDGE, Mass., Oct. 21, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a...
Ticker Report
4 months ago
Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA Get Rating) have been assigned an average recommendation of Hold from the seven brokerages that are covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold recommendation. The ...
PR Newswire
5 months ago
Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire CAMBRIDGE, Mass., Sept. 1, 2022 CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire...
Frequently Asked Questions
Frequently Asked Questions
What is Akebia Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Akebia Therapeutics Inc shares?
plus_minus_icon
How can I buy Akebia Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Akebia Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Akebia Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Akebia Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Akebia Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Akebia Therapeutics Inc?
plus_minus_icon
What percentage is Akebia Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Akebia Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.13
$0.06
(5.61%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
DBV Technologies S.A.
DBV Technologies S.A.
$1.35
$-0.03 (-2.17 %)
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc.
$31.82
$0.06 (0.19 %)
MacroGenics, Inc.
MacroGenics, Inc.
$5.71
$-0.08 (-1.38 %)
Omeros Corporation
Omeros Corporation
$5.13
$0.15 (3.01 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
DBV Technologies S.A.
DBV Technologies S.A.
$1.35
$-0.03 (-2.17 %)
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc.
$31.82
$0.06 (0.19 %)
MacroGenics, Inc.
MacroGenics, Inc.
$5.71
$-0.08 (-1.38 %)
Omeros Corporation
Omeros Corporation
$5.13
$0.15 (3.01 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00